Biogen Inc. (IDP.DE) XETRA
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Biogen Inc.
Address
225 Binney Street
Cambridge, MA 02142
United States of America (the)
Phone
617 679 2000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7605
First IPO Date
January 03, 2000
Key Executives
| Name | Title | Pay | Year Born |
| Christopher A. Viehbacher | President, Chief Executive Officer & Director | 4.62M | 1961 |
| Ginger Gregory | Executive Vice President & Chief Human Resources Officer | 1.39M | 1968 |
| Robin C. Kramer | Executive Vice President & Chief Financial Officer | 1.43M | 1966 |
| Priya Singhal | Executive Vice President & Head of Development | 1.76M | 1968 |
| Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations & Technology | 1.76M | 1973 |
| Susan H. Alexander | Executive Vice President & Chief Legal Officer | 1.94M | 1957 |
| Guy Hadari | Chief Information Officer | 0 | N/A |
| Sean Godbout | VP, Chief Accounting Officer & Global Corporate Controller | 0 | 1974 |
| Tim Power | Head of Investor Relations | 0 | N/A |
| Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | 0 | N/A |
| Adam Keeney | Executive Vice President & Head of Corporate Development | 0 | 1977 |
Description
Biogen Inc. is a prominent biopharmaceutical company dedicated to the research, development, production, and commercialization of therapeutic solutions for neurological and neurodegenerative disorders. Its extensive product lineup features treatments for multiple sclerosis (MS), including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy, the company offers SPINRAZA, and FUMADERM addresses plaque psoriasis. Furthermore, Biogen provides ADUHELM for Alzheimer's disease. The company's portfolio also encompasses various biosimilar products, such as BENEPALI (an etanercept biosimilar referencing ENBREL), IMRALDI (an adalimumab biosimilar referencing HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Beyond these, Biogen markets several anti-CD20 therapies. These include RITUXAN, used in conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, specific forms of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA is also available for non-Hodgkin's lymphoma and CLL, while GAZYVA targets CLL and follicular lymphoma. OCREVUS is another key offering, treating both relapsing and primary progressive MS. A robust pipeline underscores Biogen's future focus, with drug candidates in development across multiple areas. These include compounds for MS and neuroimmunology (BIIB135, BIIB061, BIIB091, BIIB107); Alzheimer's disease and dementia (Aducanumab, Lecanemab, BIIB076, BIIB080); neuromuscular disorders (BIIB067, BIIB078, BIIB105, BIIB100, BIIB110); Parkinson's disease and movement disorders (BIIB124, BIIB094, BIIB118, BIIB101, BIIB122); and neuropsychiatric, immunology, acute neurology, and neuropathic pain conditions (BIIB125, BIIB104, Dapirolizumab pegol, BIIB059, BIIB093, BIIB131, BIIB074). Additional biosimilars, BYOOVIZ, BIIB800, and SB15, are also progressing through various development phases. Biogen has established extensive collaboration and licensing agreements with key industry partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Founded in 1978, Biogen Inc. operates from its headquarters in Cambridge, Massachusetts.
